肠溶布地奈德治疗IgA肾病
这项前瞻性单臂多中心研究纳入168例未接受免疫抑制、已用最大耐受支持治疗的成人IgA肾病患者,给予肠溶布地奈德(IgANEF制剂,9 mg每日两次)。9个月时几何平均UACR下降66.3%,88.5%患者UACR降低≥30%,75.7%降低≥50%,平均eGFR改善+5.0 ml/min/1.73 m²,无导致停药的严重不良事件。
要点
- 肠溶布地奈德9个月降低UACR 66.3%,eGFR改善+5.0 ml/min/1.73 m²
- UACR降低≥30%和≥50%的患者比例分别为88.5%和75.7%
- 无导致停药的严重不良事件,安全性与蛋白尿疗效令人鼓舞
核心结论
- 肠溶布地奈德在IgA肾病中安全、降低蛋白尿并稳定eGFR,在缺乏其他获批药物的地区有前景。
研究设计与样本
- 前瞻性、单臂、多中心(n=6)研究,纳入168例成人IgA肾病患者,未接受免疫抑制、已用最大耐受支持治疗。
主要发现
- 9个月时(n=148)几何平均UACR下降66.3%(从1732降至583 mg/g,P<0.001)。
- UACR降低≥30%和≥50%的患者比例分别为88.5%和75.7%。
- 平均eGFR改善+5.0 ml/min/1.73 m²(P<0.001,n=137)。
- 按基线UACR(<800 vs >800 mg/g)和eGFR(<35 vs >35 ml/min/1.73 m²)分亚组,结果相似。
- 无导致停药的严重不良事件报告。
临床怎么用
- 对未接受免疫抑制、已用最大耐受支持治疗的成人IgA肾病患者,可考虑肠溶布地奈德9 mg每日两次以降低蛋白尿。
局限性
- 单臂设计,无对照组,样本量有限,随访9个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Targeted release formulation (TRF)-budesonide was the first drug approved by regulatory authorities for the management of IgA nephropathy (IgAN) but is not available in many countries. Enteric coated (EC)-budesonide is widely available, but there is a paucity of data in IgAN. METHODS: This study was a prospective, single arm, multicenter (n = 6) study of EC-budesonide (IgANEF formulation, 9 mg twice daily) on adult (age ≥ 18 years) patients with IgAN (n = 168) who were immunosuppressive naïve, on maximally tolerated supportive regimen. The primary outcome was urine albumin creatinine ratio (UACR; in %) reduction at 9 months. Secondary outcomes included estimated glomerular filtration rate (eGFR) change and proportion of patients achieving ≥ 30% and ≥ 50% UACR reduction at 9 months. A sub-roup analysis was performed for outcomes grouped by baseline proteinuria severity (UACR < 800 vs. > 800 mg/g creatinine) and kidney function (eGFR < 35 vs. > 35 ml/min per 1.73 m2). RESULTS: The mean age of the cohort was 36.1 ± 11.0 years with 97 males (57.1%). At 9 months (n = 148), geometric mean UACR decreased by 66.3% (from 1732 to 583 mg/g, P < 0.001). UACR response rates were 88.5% for ≥ 30% reduction and 75.7% for ≥ 50% reduction. Mean eGFR improved +5.0 ml/min per 1.73 m2 (P < 0.001, n = 137). The outcome was similar in subgroups of both UACR and eGFR. There were no serious adverse events reported requiring discontinuation. CONCLUSION: In this prospective multicenter, single arm study of EC-budesonide in IgAN, the safety, proteinuria reduction, and eGFR stabilization were encouraging. The drug has promising efficacy in regions where other approved drugs are unavailable.
引用
- Gulati S, Chaudhary AR, Chauhan S, et al. Enteric Budesonide Treatment in IgA Nephropathy. Kidney Int Rep. 2026. PMID: 42006206. doi:10.1016/j.ekir.2026.106412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。